# PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

> **NCT06590194** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Suzhou Puhe Pharmaceutical Technology Co., LTD** · enrollment: 96 (estimated)

## Conditions studied

- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** PH009-1 tablet

## Key facts

- **NCT ID:** NCT06590194
- **Lead sponsor:** Suzhou Puhe Pharmaceutical Technology Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-08-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06590194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06590194, "PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06590194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*